Kampe C E, Hart S, Miller R A, Lichtenstein A, Kyle R A, Berenson J R
Wadsworth Cancer Center, Department of Veterans Administration Medical Center, Los Angeles, CA 90073.
Br J Haematol. 1994 Aug;87(4):719-24. doi: 10.1111/j.1365-2141.1994.tb06729.x.
We have previously demonstrated the expression of shared idiotypes by the paraproteins from approximately one-quarter of patients with multiple myeloma (MM). We have now investigated whether similar cross-reactivity is expressed in the paraproteins of patients with monoclonal gammopathy of undetermined significance (MGUS), using a panel of 32 monoclonal antibodies (MAB) generated against follicular B cell lymphomas. The paraproteins from 76/409 (19%) patients with MGUS reacted with at least one of 23 different anti-idiotypic antibodies used in this study. 18 MABs demonstrated reactivity with more than one patient's paraprotein. Moreover, 10 MABs reacted frequently (with 5-22 paraproteins). Over half (41/76) of the reactive patients' paraproteins reacted with more than one MAB from this panel. This frequency of anti-idiotypic reactivity was similar to that of previously studied patients with myeloma, chronic lymphocytic leukaemia (CLL), and follicular B-cell lymphomas. There was no correlation between specific anti-idiotypic reactivity and the propensity to develop serious disease (MM, macroglobulinaemia, amyloidosis, or other lymphoproliferative disorders) in patients with MGUS. These results suggest that MGUS is derived from cells producing antibodies that are similar to those of other B-cell malignancies and that the pattern of idiotype expression is irrelevant to malignant potential.
我们之前已证明,约四分之一的多发性骨髓瘤(MM)患者的副蛋白可表达共同独特型。我们现在使用一组针对滤泡性B细胞淋巴瘤产生的32种单克隆抗体(MAB),研究意义未明的单克隆丙种球蛋白病(MGUS)患者的副蛋白中是否表达类似的交叉反应性。409例MGUS患者中有76例(19%)的副蛋白与本研究中使用的23种不同抗独特型抗体中的至少一种发生反应。18种MAB与不止一名患者的副蛋白发生反应。此外,10种MAB经常发生反应(与5 - 22种副蛋白反应)。超过一半(41/76)有反应的患者的副蛋白与该组中的不止一种MAB发生反应。这种抗独特型反应的频率与先前研究的骨髓瘤、慢性淋巴细胞白血病(CLL)和滤泡性B细胞淋巴瘤患者相似。MGUS患者中特定的抗独特型反应与发生严重疾病(MM、巨球蛋白血症、淀粉样变性或其他淋巴增殖性疾病)的倾向之间没有相关性。这些结果表明,MGUS源自产生与其他B细胞恶性肿瘤相似抗体的细胞,且独特型表达模式与恶性潜能无关。